Ca(OH)2 as intracanal medicament

PreclinicalSmall molecule

AAristotle University Of Thessaloniki

Ca(OH)2 as intracanal medicament is one of 45 small molecule programs targeting ESS. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ESSRecruiting

ESSPreclinical

Recruiting

Competition

Competitive Landscape

56 competitors in ESS

#DrugCompanyPhaseTrials

Lexapro

AbbVie

Approved

7 2

Proamatine

Takeda

Approved

2 3

Quviviq

Idorsia Pharmaceuticals Ltd.

Approved

1 4

Opdualag

Bristol-Myers Squibb

Phase 2

2 5

Opdivo

Bristol-Myers Squibb

Phase 2

2 6

Darzalex

Johnson & Johnson

Phase 2

1 7

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

1 8

Decadron

AAspen Global Incorporated

Phase 2

1 9

Kyprolis

VVirionyx Corporation Limited

Phase 2

1 10

Mineral Trioxide Aggregate

JJordan University of Science and Technology

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

ESS1 trial

Multiple-Visit RCT in Teeth With SAP: Interappointment Dressing or Not?

Recruiting·—·N/A·NCT06447519·110 enrolled

Chronic Apical Periodontitis1 trial

The Effect of Systemic Administration of Probiotics and Intra-Canal Medications on Level of Nuclear Factor Kappa B Ligand, Osteoprotegerin and Postoperative Pain in Patients With Chronic Apical Periodontitis: (Randomized Controlled Clinical Trial)

Completed·AAin Shams University·Approved·NCT07683520·72 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Ca(OH)2 as intracanal medicament. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ca(OH)2 as intracanal medicament compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ca(OH)2 as intracanal medicament. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Aristotle University Of Thessaloniki company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AAristotle University Of Thessaloniki

Ca(OH)2 as intracanal medicament

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

ESS1 trial

Chronic Apical Periodontitis1 trial

References

Drug Info

Quick Facts

Related News